The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions …

Find resources including downloadable guides, patient support and more with AUSTEDO XR® extended release tablets for Tardive Dyskinesia (TD). See safety info and Boxed Warning.

Dec 30, 2016 · These recommendations are consistent (a) with the other labeled indication for AUSTEDO in the treatment of chorea associated with Huntington’s disease and (b) in principle with …

Deutetrabenazine (Austedo) can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of deutetrabenazine …

Mar 9, 2025 · The safety and effectiveness of AUSTEDO XR and AUSTEDO have not been established in pediatric patients for the treatment of Tourette syndrome. Efficacy was not demonstrated in two …

Aug 1, 2025 · Coverage Guidelines Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding …

Signs and symptoms of parkinsonism and akathisia, including restlessness and agitation, especially in the two weeks following a dose increase. TD:99981231160000-0800 AIMS weekly for the first 12 for …

Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.

AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …

Jul 28, 2025 · Updated in 2020, American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia (Third Edition) and A Modified Delphi Consensus Study of the …